Moderna (MRNA) Issues 2024 Shareholders Letter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Oppenheimer lifts Moderna (MRNA) rating on key 2024/2025 catalysts
January 2, 2024 8:19 AM ESTModerna (NASDAQ: MRNA) shares were raised to Outperform from Perform at Oppenheimer on Tuesday, with analyst Hartaj Singh assigning the stock a $142 per share price target.
The analyst told investors in a note that key factors for the upgrade are increasing visibility on COVID-19... More
